Clinical Trial Detail

NCT ID NCT01076543
Title Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors National Cancer Institute (NCI)
Indications

Hodgkin's lymphoma

non-Hodgkin lymphoma

Therapies

Temsirolimus + Lenalidomide

Age Groups: adult

No variant requirements are available.